Citi analyst Samantha Semenkow raised the firm’s price target on Spyre Therapeutics (SYRE) to $97 from $64 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Julian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
- Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders
- Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)
- Spyre Therapeutics: Buy Rating Reaffirmed as External Combo Data Support IBD Strategy; $95 Price Target Unchanged
- Spyre Therapeutics price target raised to $95 from $64 at JonesResearch